Results 181 to 185 of about 2,131 (185)

Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials

Cephalalgia, 2019
David W Dodick, Ernesto Aycardi, Marcelo E Bigal   +2 more
exaly  

Migräne: Fremanezumab ist wirksam

NeuroTransmitter, 2018
openaire   +1 more source

Efficacy of fremanezumab in migraine prevention

Journal of the Neurological Sciences
Daniel Neto, Nathália Figuerêdo, Larissa Falcão, Wagner Horta   +3 more
openaire   +1 more source

Fremanezumab auf dem Weg

NeuroTransmitter, 2018
openaire   +1 more source

Atogepant/Botulinum-Toxin-A/Fremanezumab

Reactions Weekly
openaire   +1 more source